FREQUENCY AND ASSOCIATION OF 1691 (G>A) FVL, 20210 (G>A) PT AND 677 (C>T) MTHFR WITH DEEP VEIN THROMBOSIS IN THE POPULATION OF BOSNIA AND HERZEGOVINA
Jusić-Karić A, Terzić R, Jerkić Z, Avdić A, Pođanin M
*Corresponding Author: Amela Jusić-Karić, Ph.D., Faculty of Science and Mathematics, University of Tuzla, Univerzitetska 4, 75 000 Tuzla, Bosnia and Herzegovina. Tel: +387-61-289-217. Fax: +387-35-320-861. E-mail: amela.jusic @untz.ba
page: 43

REFERENCES

1. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993; 72(4): 477-480. 2. Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case control study. Biochemia Medica. 2010; 20(2): 229-235. 3. Segers K, Dahlback B, Gerry AFN. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost. 2007; 98(3): 530-542. 4. Katcharin A, Napaporn A, Timaluck S, Pantep A. Prevalence of factor V Leiden (G1691A) and prothrombin gene mutation (G20210A) among different ethnic group in Thai hospitals. J Hematol Transfus Med. 2012; 22(2): 115-120. 5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C). Blood. 1995; 85(6): 1504-1508. 6. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16): 1305-1307. 7. Herrmann FH, Koesling M, Schrŏder W, Altman R, Jiménez Bonilla R, Lopaciuk S, et al. Prevalence of factor V Leiden mutation in various population. Genet Epidemiol. 1997; 14(4): 403-411. 8. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88(10): 3698-3703. 9. Bavikatty N, Kileen A, Akel N, Normolle D, Schmaier A. Association of the prothrombin G20210A mutation with factor V Leiden in a midwestern American population. Am J Clin Pathol. 2000; 114(2): 272-275. 10. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylene-tetrahydofolate reductase gene and risk of venous throm-boembolism. Br J Haematol. 1997; 97(4): 804-806. 11. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis. N Engl J Med. 2005; 3(2): 292-299. 12. Karic A, Terzic R, Jerkic Z, Mustedanagic-Mujanovic J. The frequency of C677T methylentetrahidrofolate reductase (MTHFR) polymorphism in Southern East Bosnian population. J Biomet Biostat. 2013; 4(4): 1-4. 13. Adler G, Agnieszka G, Valjevac A, Czerska E, Kiseljaković E, Salkic N. Prevalence of genetic prothrombotic risk factors: 1691G>A FV, 20210G>A PT and 677 C>T MTHFR mutations in Bosnian population. Ann Hum Biol. 2014; 42(6): 576-580. 14. Bertina RM, Koelman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation facto V associated with resistance to activated protein C. Nature. 1996; 369(6475): 64-67. 15. Froost P, Blom HJ, Milos R, Gazette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylene-tetrahydrofolatereductase. Nat Genet. 1995; 10(1): 111-113. 16. McHugh M. The odds ratio: Calculation, usage and inerpretation. Biochemia Medica. 2009; 19(2): 120-126. 17. Kejzer M, den Hajer M, Blom HJ, Bos GMJ, Willems HPJ, Gerrits WBJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydro- folate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost. 2002; 88(5): 72-78. 18. Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P, et al. Factor V Leiden, prothrombin 20210 G>A, methylenetetrahydrofolate reductase 677C>T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy related venous thromboembolism. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2): 157-163. 19. Berge E, Haug KB, Sandset EC, Haughbro KK, Turkovic M, Sandset PM. The factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ishemic stroke and atrial fibrillation. Stroke. 2007; 38(3): 106-171. 20. Pauer H, Voigt-Tschirschwitz T, Hinney B, Burfeind P, Wolf C, Emons G, et al. Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. Acta Obstet Gynecol Scand. 2003; 82(10): 942-947. 21. Koster T, Roosendal FR, de Ronde H, Riet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilila study. Lancet. 1993; 342(8886-8887): 1503-1506. 22. Coen D, Zadro R, Honović, Banfic Lj, Rukavina- Stavljenic A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001; 42(4): 488-492. 23. Đorđevic V, Rakicevic Lj, Mikovic D, Kovac M, Miljic P, Radojkovic D, et al. Prevalence of factor V Leiden, factor V Cambridge, factor II G20210A and meth-ylenetetrahydrofolatereductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol. 2004; 112(4): 227-229. 24. Arsov T, Miladinova D, Spiroski M. Factor V Leiden is associated with higher risk deep venous thrombosis of large blood vessels. Croat Med J. 2006; 47(3): 433-439. 25. Jadaon MM. Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011054. doi: 10.4084/ MJHID.2011.054. 26. Isotalo PA, Donnely JG. Prevalence of methylene- tetrahydrofolatereductase mutations in patients with venous thrombosis. Mol Diagn. 2000; 5(1): 59-66. 27. Moglinicka-Nizankowska E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J. 2003; 21(1): 25-30. 28. D’Angelo A, Beltramentti C. Venous disease. In: Carmel R, Jacobsen DW, Eds. Homocysteine in Health and Disease. Cambridge, Cambridgeshire, UK: Cambridge University Press. 2001:401-414. 29. Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylenetetrahydrofolat reductase (MTHFR) and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE). Am J Hematol. 2003; 72(3): 192-200. 30. Beyan C, Beyan E. MTHFR 677 CT gene polymorphism is not a risk factor for venous thromboembolism. Çukurova Med J. 2014; 39(1): 189-190. 31. Ehrenforth S, von Fepka-Prondsinski M, Aygoren- Pursun E, Nowak-Gottl U, Scharrer I, Ganser A. Study of the prothrombin gene 20210GA variant in FV:Q506 car-riers in the relationship to the presence or absence of juvenile venous thromboemolism. Arterioscler Thromb Vasc Biol. 1999; 19(2): 276-280. 32. Zoller B, Svanson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994; 94(6): 2521-2524. 33. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilia and is not increased in frequency of artery disease. Arterioscler Thromb Vasc Biol. 1997; 17(11): 2418-2422. 34. De Stefano V, Martinelli I, Mannuccio P, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999; 341(11): 801-806. 35. Simone B, De Stefano V, Leoncini E, Zacho, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetetra-hydrofolate reductase C677T: A meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013; 28(8): 621-647.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006